CRISPR Therapeutics

CRISPR Therapeutics: Follow-on Offering Funding Round

CRISPR Therapeutics has successfully raised $337M in Follow-on Offering funding, reaching a valuation of $8B.

Company Overview

Gene-based medicines using CRISPR/Cas9

Funding Details

The Follow-on Offering round was led by Versant Ventures, with participation from Bayer, Vertex Pharmaceuticals.

Company Information

• Headquarters: Aeschenvorstadt 36, Basel 4051, Switzerland
• Founded: 2013
• Employees: 500+
• Category: Biotech

Investment

CRISPR Therapeutics plans to use the funds to accelerate product development, expand its team, and scale operations globally.

About the Investors

• Versant Ventures: Verified investor in Follow-on Offering
• Bayer: Verified investor in Follow-on Offering
• Vertex Pharmaceuticals: Verified investor in Follow-on Offering